For these cancers, the therapy of choice is endocrine therapy, which aims to deprive the tumour of oestrogens or directly block ERα activity, respectively, through the use of aromatase inhibitors or antioestrogens such as the tamoxifen [7, 8]. This evidence concerns the gene ESR1 and cancer.